This is an accelerated approval based on a single-arm phase-2 cohort (n=120) in which ORR=50%, CR=13%, and median DoR=8.3 months. Jaypirca is a non-covalent BTK inhibitor.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”